Cue Historical Financial Ratios
| CUE Stock | USD 1.04 0.04 3.70% |
Cue Biopharma is presently reporting on over 100 different financial statement accounts. To analyze all of these accounts together requires a lot of time and effort. However, using these accounts to derive some meaningful and actionable indicators such as Dividend Yield of 0.0, PTB Ratio of 3.09 or Days Sales Outstanding of 99.03 will help investors to properly organize and evaluate Cue Biopharma financial condition quickly.
Cue |
About Cue Financial Ratios Analysis
Cue BiopharmaFinancial ratios are relationships based on a company's financial information. They can serve as useful tools to evaluate Cue Biopharma investment potential. Financial ratio analysis can also be defined as the process of presenting financial ratios, which are mathematical indicators calculated by comparing key financial information appearing on Cue financial statements. Financial ratios are useful tools that help investors analyze and compare relationships between different pieces of financial information across Cue Biopharma history.
Cue Biopharma Financial Ratios Chart
Add Fundamental
Price To Sales Ratio
Price to Sales Ratio is figured by comparing Cue Biopharma stock price to its revenues. An advantage to using Price to Sales ratio is that it is based on Cue Biopharma sales, a figure that is much harder to manipulate than other Cue Biopharma multiples. Because sales tend to be more stable P/S ratio can be a good tool for screening cyclical companies fluctuating earnings patterns. A valuation ratio that compares a company's stock price to its revenues, calculated by dividing the company's market cap by its total sales or revenue over a 12-month period.Ptb Ratio
Price-to-Book ratio, a financial valuation metric used to compare a company's current market price to its book value. It provides insight into the value that market participants place on the company's equity relative to its net asset value.Book Value Per Share
The ratio of equity available to common shareholders divided by the number of outstanding shares. This measure represents the value per share of a company according to its financial statements.Invested Capital
Invested capital represents the total cash investment that shareholders and debt holders have contributed to Cue Biopharma. There are two different methods for calculating Cue Biopharma invested capital: operating approach and financing approach. Understanding Cue Biopharma invested capital allows investors to calculate measures of performance such as return on invested capital or return on capital employed.Most ratios from Cue Biopharma's fundamentals are interrelated and interconnected. However, analyzing fundamentals ratios one by one will only give a small insight into Cue Biopharma current financial condition. On the other hand, looking into the entire matrix of fundamentals ratios, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Cue Biopharma. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in employment. For information on how to trade Cue Stock refer to our How to Trade Cue Stock guide.At present, Cue Biopharma's Cash Per Share is projected to increase slightly based on the last few years of reporting. The current year's Tangible Book Value Per Share is expected to grow to 1.40, whereas PTB Ratio is forecasted to decline to 3.09.
| 2021 | 2022 | 2023 | 2024 (projected) | Days Sales Outstanding | 76.77 | 16.78 | 112.89 | 99.03 | PTB Ratio | 5.4 | 1.55 | 3.26 | 3.09 |
Cue Biopharma fundamentals Correlations
Click cells to compare fundamentals
Cue Biopharma Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Cue Biopharma fundamentals Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Price To Sales Ratio | 101.19 | 113.78 | 23.68 | 81.59 | 22.0 | 20.9 | |
| Ptb Ratio | 6.41 | 4.55 | 5.4 | 1.55 | 3.26 | 3.09 | |
| Book Value Per Share | 2.48 | 2.75 | 2.09 | 1.84 | 0.81 | 1.4 | |
| Free Cash Flow Yield | (0.0881) | (0.0922) | (0.11) | (0.41) | (0.33) | (0.35) | |
| Operating Cash Flow Per Share | (1.4) | (1.13) | (1.24) | (1.17) | (0.87) | (0.92) | |
| Stock Based Compensation To Revenue | 1.89 | 3.32 | 0.77 | 7.63 | 1.49 | 1.42 | |
| Capex To Depreciation | 0.008973 | 0.56 | (0.51) | 0.0945 | 0.11 | 0.1 | |
| Pb Ratio | 6.41 | 4.55 | 5.4 | 1.55 | 3.26 | 3.09 | |
| Ev To Sales | 90.06 | 92.31 | 20.05 | 55.65 | 15.84 | 15.05 | |
| Roic | (1.16) | (0.63) | (0.54) | (0.003754) | (1.15) | (1.21) | |
| Net Income Per Share | (1.66) | (1.56) | (1.41) | (1.48) | (1.11) | (1.16) | |
| Payables Turnover | 31.14 | 16.2 | (0.69) | 0.66 | 10.88 | 6.51 | |
| Sales General And Administrative To Revenue | 3.68 | 4.64 | 1.16 | 12.98 | 3.04 | 2.89 | |
| Research And Ddevelopement To Revenue | 7.95 | 10.63 | 2.77 | 30.98 | 7.43 | 7.06 | |
| Capex To Revenue | 0.0134 | 0.19 | 0.0611 | 0.14 | 0.16 | 0.15 | |
| Cash Per Share | 2.7 | 2.96 | 2.06 | 2.14 | 1.06 | 1.51 | |
| Pocfratio | (11.36) | (11.04) | (9.11) | (2.43) | (3.02) | (3.17) | |
| Capex To Operating Cash Flow | (0.001505) | (0.0183) | (0.0235) | (0.004084) | (0.003676) | (0.00386) | |
| Pfcf Ratio | (11.34) | (10.85) | (8.9) | (2.42) | (3.02) | (3.17) | |
| Days Payables Outstanding | 11.72 | 22.53 | (531.84) | 551.93 | 33.54 | 31.87 | |
| Income Quality | 0.68 | 0.84 | 0.73 | 0.88 | 0.79 | 0.61 | |
| Roe | (1.15) | (0.67) | (0.57) | (0.8) | (1.37) | (1.44) | |
| Ev To Operating Cash Flow | (10.11) | (8.96) | (7.71) | (1.66) | (2.18) | (2.29) | |
| Pe Ratio | (2.43) | (9.53) | (8.01) | (1.92) | (2.38) | (2.5) | |
| Return On Tangible Assets | (0.51) | (0.45) | (0.53) | (0.58) | (0.82) | (0.87) | |
| Ev To Free Cash Flow | (10.1) | (8.8) | (7.54) | (1.65) | (2.18) | (2.29) | |
| Earnings Yield | (0.41) | (0.1) | (0.12) | (0.52) | (0.42) | (0.44) | |
| Net Debt To E B I T D A | 1.07 | 1.54 | 1.2 | 0.64 | 0.73 | 0.7 | |
| Current Ratio | 5.24 | 5.36 | 5.35 | 6.68 | 3.01 | 2.86 | |
| Tangible Book Value Per Share | 2.48 | 2.75 | 2.09 | 1.84 | 0.81 | 1.4 | |
| Graham Number | 9.63 | 9.83 | 8.15 | 7.84 | 4.5 | 5.38 | |
| Shareholders Equity Per Share | 2.48 | 2.75 | 2.09 | 1.84 | 0.81 | 1.4 | |
| Capex Per Share | 0.002103 | 0.0207 | 0.0292 | 0.00479 | 0.005508 | 0.005233 | |
| Graham Net Net | 2.29 | 2.28 | 1.56 | 1.42 | 0.55 | 0.53 |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Cue Biopharma is a strong investment it is important to analyze Cue Biopharma's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Cue Biopharma's future performance. For an informed investment choice regarding Cue Stock, refer to the following important reports:Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Cue Biopharma. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in employment. For information on how to trade Cue Stock refer to our How to Trade Cue Stock guide.You can also try the Theme Ratings module to determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Cue Biopharma. If investors know Cue will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Cue Biopharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.91) | Revenue Per Share 0.172 | Quarterly Revenue Growth 0.923 | Return On Assets (0.52) | Return On Equity (1.39) |
The market value of Cue Biopharma is measured differently than its book value, which is the value of Cue that is recorded on the company's balance sheet. Investors also form their own opinion of Cue Biopharma's value that differs from its market value or its book value, called intrinsic value, which is Cue Biopharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Cue Biopharma's market value can be influenced by many factors that don't directly affect Cue Biopharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Cue Biopharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Cue Biopharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Cue Biopharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.